Nuclear Medicine News and Research

RSS

Nuclear medicine is a branch or specialty of medicine and medical imaging that uses radioactive isotopes (radionuclides) and relies on the process of radioactive decay in the diagnosis and treatment of disease. In nuclear medicine procedures, radionuclides are combined with other chemical compounds or pharmaceuticals to form radiopharmaceuticals.

Imaging algorithm distributed in top-down fashion reduces unnecessary cervical spine radiographs

An imaging algorithm produced by a radiology department and distributed through the medical director's office, in a top-down fashion, enabled a large, academic medical center to significantly reduce the number of unnecessary cervical spine radiographs (X-rays) in the emergency department, according to a study published in the July issue of the Journal of the American College of Radiology.

2 Jul 2010

SNMTS honors contributions in nuclear medicine and molecular imaging at 57th Annual Meeting

SNM's Technologist Section (SNMTS)-an international scientific and medical organization-recognized the contributions and work to the field of nuclear medicine and molecular imaging during its 57th Annual Meeting in Salt Lake City. Several awards ceremonies were held to recognize the value that SNMTS members play in advancing the diagnosis and treatment of heart disease, cancer and neurological conditions.

2 Jul 2010

Novel imaging agents and techniques can revolutionize medical imaging science: JNM

A study published in the July issue of The Journal of Nuclear Medicine (JNM) reports on investigative research of a novel optical imaging technique called "Cerenkov luminescence imaging (CLI)." According to the authors, the technique could lead to the faster and more cost-effective development of radiopharmaceuticals for the diagnosis and treatment of cancer and other conditions.

2 Jul 2010

New tool could aid in diagnosing Alzheimer's, track disease progression

A trial of a novel radioactive compound readily and safely distinguished the brains of Alzheimer's disease patients from healthy volunteers on brain scans and opens the doors to making such imaging available beyond facilities that can manufacture their own radioactive compounds.

29 Jun 2010

Probactive Biotech, Dalat Nuclear Research Institute enter agreement to co-develop cancer drugs

Probactive Biotech, Inc., a Garden Grove, California-based corporation, has entered into an agreement with Dalat Nuclear Research Institute to co-develop a number of cancer drugs, utilizing combinations of antitumor antibodies and antitumor radioactive compounds. Antitumor antibodies have the ability to take antitumor compounds directly to the tumor sites within the body.

22 Jun 2010

Ohio Third Frontier helps drive innovation and opportunity in biomedical industry

Ohio Third Frontier, and the strategic investments made by the program to bolster Ohio's biomedical imaging industry, serve as a national model for success and are the primary reason behind Ohio's position as a national hub for innovation and opportunity in the thriving biomedical industry.

22 Jun 2010

Positron sells four Attrius PET scanners

Positron Corporation, a leader as a molecular imaging and solutions company specializing in the field of Nuclear Cardiology, announces the sales of four Attrius™ PET scanners to prominent cardiology practices and orders six Attrius™ PET scanners from its joint venture, Neusoft Positron Medical Systems for immediate delivery.

21 Jun 2010

Bracco release confirms Positron's market growth prediction of cardiac PET

Positron Corporation, a leader as a molecular imaging and solutions company specializing in the field of Nuclear Cardiology, cites an article posted on AuntMinnie.com, the largest community website for medical imaging professionals, relating to the growth in cardiac PET.

19 Jun 2010

Naviscan announces presentations on PEM technology at Society of Nuclear Medicine Annual Meeting

Naviscan's Positron Emission Mammography (PEM) technology was the focus of several presentations and discussions at the Society of Nuclear Medicine Annual Meeting in Salt Lake City. The focus represents a growing interest and validation of how PEM can play an important role in the fight against breast cancer.

18 Jun 2010

Molecular imaging fusion with CT anatomy results in precise localization of parathyroid lesions: Research

SNM's 2010 Image of the Year illustrates the potential of hybrid molecular imaging to provide precise information about the location and function of a condition known as "hyperparathyroidism." Researchers selected this image from more than 1,500 studies presented over the course of four days during SNM's 57th Annual Meeting in Salt Lake City.

16 Jun 2010

New computer program allows early diagnosis of Alzheimer's disease

Researchers of the University of Granada have developed a new computer program that allows early diagnosis of Alzheimer's disease through processed images.

11 Jun 2010

Researchers develop new computer program for early diagnosis of Alzheimer's disease

Researchers of the University of Granada have developed a new computer program that allows early diagnosis of Alzheimer's disease through processed images. This new system has enhanced successful early diagnosis of Alzheimer's disease up to 90%, which is an important progress within this area of study.

10 Jun 2010

Spectrum Dynamics commences ultra low dose trials of radiopharmaceutical agents with D-SPECT technology

Cardiovascular imaging accounts for 30 percent of all the radiation patients receive in the U.S. and today, at the Society for Nuclear Medicine annual meeting, Spectrum Dynamics announced it has begun clinical studies to show that its D-SPECT™ technology can accommodate significantly lower doses of radiopharmaceutical agents so the total radiation exposure to patients and staff is much lower compared to conventional cardiac imaging.

10 Jun 2010

Lantheus presents preliminary Phase 2 data of flurpiridaz F18 injection PET MPI at 57th SNM

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced preliminary Phase 2 data describing the methodology used to define an imaging protocol for a one-day rest-stress myocardial perfusion imaging test using its novel investigational PET imaging agent flurpiridaz F 18 injection (formerly known as BMS747158).

10 Jun 2010

TF2 bispecific antibody pretargeted therapy prolongs survival in animal model of human colonic cancer

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that pretargeted therapy with TF2, a bispecific antibody against carcinoembryonic antigen (CEA) and a small peptide, delayed tumor growth and prolonged survival in an animal model of human colonic cancer.

10 Jun 2010

GE Healthcare presents interim phase 2 study results of fluciclatide

GE Healthcare, a unit of the General Electric Company, today presented interim phase 2 study results of fluciclatide, in collaboration with the National Cancer Institute, a federal research agency and part of the National Institutes of Health. Fluciclatide is an integrin-targeted radiopharmaceutical under development for oncology PET imaging.

10 Jun 2010

PulmoBind product candidate has potential for early diagnosis of PH in pediatric population

Pulmo BioTech Inc. has announced that early indications are that its PulmoBind product candidate has the potential for early diagnosis of Pulmonary Hypertension in the pediatric population. PH is a potentially life threatening and crippling disease; it is also very hard to diagnose.

9 Jun 2010

GE Healthcare to present anti-[18F]FACBC phase 1 study results at Society of Nuclear Medicine annual meeting

GE Healthcare, a unit of the General Electric Company, today will present results of a phase 1 study of anti-[18F]FACBC at the 57th annual meeting of the Society of Nuclear Medicine in Salt Lake City, Utah. The presentation closely follows the launch of the phase 2 clinical development program for anti-[18F]FACBC, which was initially discovered and developed by Emory University, Atlanta, Georgia, and was licensed to Nihon Medi-Physics Co., Ltd. (NMP) of Japan.

9 Jun 2010

PET imaging with flurpiridaz F 18 better than technetium-99m sestamibi SPECT for CAD detection

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced preliminary data from a single site participating in the multicenter Phase 2 clinical trial that showed that Positron Emission Tomography (PET) imaging with its novel investigational agent flurpiridaz F 18 injection (formerly known as BMS747158) provided better image quality than technetium-99m sestamibi single photon emission computed tomography (SPECT), the current standard for the non-invasive detection of coronary artery disease (CAD).

8 Jun 2010

GE Healthcare highlights molecular imaging technologies to help clinicians improve patient experiences

Focusing on helping clinicians improve experiences for their patients, GE Healthcare is highlighting an innovative portfolio of molecular imaging technologies and agents at the 57th annual meeting of the Society of Nuclear Medicine, June 5-9, in Salt Lake City.

7 Jun 2010

Nuclear Medicine News and Research

Further Reading

Imaging algorithm distributed in top-down fashion reduces unnecessary cervical spine radiographs

SNMTS honors contributions in nuclear medicine and molecular imaging at 57th Annual Meeting

Novel imaging agents and techniques can revolutionize medical imaging science: JNM

New tool could aid in diagnosing Alzheimer's, track disease progression

Probactive Biotech, Dalat Nuclear Research Institute enter agreement to co-develop cancer drugs

Ohio Third Frontier helps drive innovation and opportunity in biomedical industry

Positron sells four Attrius PET scanners

Bracco release confirms Positron's market growth prediction of cardiac PET

Naviscan announces presentations on PEM technology at Society of Nuclear Medicine Annual Meeting

Molecular imaging fusion with CT anatomy results in precise localization of parathyroid lesions: Research

New computer program allows early diagnosis of Alzheimer's disease

Researchers develop new computer program for early diagnosis of Alzheimer's disease

Spectrum Dynamics commences ultra low dose trials of radiopharmaceutical agents with D-SPECT technology

Lantheus presents preliminary Phase 2 data of flurpiridaz F18 injection PET MPI at 57th SNM

TF2 bispecific antibody pretargeted therapy prolongs survival in animal model of human colonic cancer

GE Healthcare presents interim phase 2 study results of fluciclatide

PulmoBind product candidate has potential for early diagnosis of PH in pediatric population

GE Healthcare to present anti-[18F]FACBC phase 1 study results at Society of Nuclear Medicine annual meeting

PET imaging with flurpiridaz F 18 better than technetium-99m sestamibi SPECT for CAD detection

GE Healthcare highlights molecular imaging technologies to help clinicians improve patient experiences

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News